These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25450281)

  • 21. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 25. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Anai S; Iwama E; Yoneshima Y; Otsubo K; Tanaka K; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Dec; 126():156-161. PubMed ID: 30527181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
    Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
    Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.
    Xiao XG; Xia S; Zou M; Mei Q; Zhou L; Wang SJ; Chen Y
    Onco Targets Ther; 2015; 8():3575-83. PubMed ID: 26664141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
    World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
    Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
    Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
    World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
    Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
    J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
    Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
    Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
    J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
    Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
    Deng C; Lou Y; Gao Y; Deng B; Su F; Jia L
    Trials; 2020 May; 21(1):370. PubMed ID: 32357899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.